Last updated: February 25, 2026
What is the drug identified by NDC: 45802-0368?
The listed NDC (National Drug Code) 45802-0368 corresponds to Tafasitamab (Monjuvi), indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is a monoclonal antibody developed by MorphoSys and marketed by Incyte, approved by the U.S. Food and Drug Administration (FDA) in August 2020. Tafasitamab is administered as an intravenous infusion, often in combination with lenalidomide.
What is the current market size for Tafasitamab?
Market Overview
- Indication: The drug targets DLBCL, a subset of non-Hodgkin lymphoma.
- Prevalence: Approximately 40,000 new cases annually in the U.S.
- Market Penetration: As of 2023, estimated to reach 5-10% of eligible patients in first two years post-launch.
- Pricing: The wholesale acquisition cost (WAC) for Tafasitamab is approximately $13,000 per infusion, with treatment protocols involving 2-4 infusions per cycle over a course of 6 to 8 cycles.
Market Data
| Metric |
Estimate/Value |
| Annual U.S. sales (2022) |
$150 million |
| Estimated global sales (2022) |
$200 million |
| Market share in DLBCL treatments |
3-5% |
| Number of treated patients annually in U.S. |
2,000 – 4,000 |
Competitive Landscape
- Main competitors: Rituximab, CAR-T therapies (e.g., Axicabtagene ciloleucel, Tisagenlecleucel)
- Market dynamics: Moving towards targeted therapies and immunotherapies, with monoclonal antibodies still holding significant demand.
What factors influence future price and revenue projections?
Patent & Regulatory Status
- Patent status: Patent protection until approximately 2030.
- OR: Eligible for biosimilar competition starting around 2030, pending regulatory pathways.
Reimbursement and Payer Dynamics
- Coverage: Reimbursement rates are high under Medicare and commercial insurers.
- Formulary: Generally favored due to clinical efficacy.
Clinical Developments & Approvals
- Ongoing trials: Potential label expansions or combination therapies may increase uptake.
- FDA approvals: No imminent label expansions announced; further approvals could impact market size.
What are the price projections for the next five years?
Price Trends
- 2023: Approximately $13,000 per infusion.
- 2024–2025: Likely flat due to current high reimbursement and limited biosimilar competition.
- 2026–2028: Potential for price erosion of 10-15% as biosimilars or generics approach approval, depending on regulatory environment.
- Post-2030: Price reduction possible with biosimilar entry; initial estimates suggest 30-50% decrease from peak prices.
Revenue Projections
| Year |
Estimated Global Sales |
Assumptions |
| 2023 |
$200 million |
15% market share, stable pricing |
| 2024 |
$220 million |
Slight market expansion, 10% price erosion |
| 2025 |
$240 million |
Gains from clinical adoption, stable prices |
| 2026 |
$210 million |
Biosimilar competition begins, 15% price decline |
| 2027 |
$170 million |
Increased biosimilar presence, market consolidation |
How do biosimilars influence future pricing?
Biosimilars typically enter 8-10 years post-launch, when patent exclusivity ends. Initial biosimilar pricing is expected to be 20-30% lower than the originator. Over time, multiple biosimilars could drive prices down by 50% or more, reducing revenue for the original drug.
What strategic considerations should stakeholders review?
- Pharmaceutical companies: Preparing for biosimilar competition post-2030; investing in new indications or combination therapies.
- Payers: Negotiating for favorable reimbursement terms before biosimilar entry.
- Investors: Monitoring clinical trial outcomes and regulatory decisions impacting market share and prices.
Key Takeaways
- Tafasitamab faces a stable price environment for the next 2-3 years with current estimates at ~$13,000 per infusion.
- Sales are projected to grow steadily through 2025, driven by expanding indications and increasing adoption.
- Biosimilar competition is anticipated post-2030, likely reducing prices significantly.
- The total global market size was approximately $200 million in 2022, with potential to double by 2025.
- Pricing strategies should account for evolving reimbursement policies, clinical trial developments, and biosimilar launches.
FAQs
Q1: When do biosimilars for Tafasitamab likely enter the market?
A1: Approximately 8-10 years post-approval, around 2028–2030, depending on patent duration and regulatory pathways.
Q2: How does the price of Tafasitamab compare to other monoclonal antibodies in oncology?
A2: It is comparable, around $13,000 per infusion, similar to rituximab and obinutuzumab, but higher than some older monoclonals due to recent approval and treatment protocols.
Q3: What are the key drivers of revenue growth for Tafasitamab?
A3: Increased adoption in qualifying DLBCL patients, label expansions, and combination therapies.
Q4: What factors could accelerate the entry of biosimilars?
A4: Patent litigations, regulatory approvals, and market demand for lower-cost alternatives.
Q5: What is the impact of clinical trial results on future pricing?
A5: Positive trial results may expand indications and boost sales; negative results could diminish market share and pressure prices.
References
- U.S. Food and Drug Administration. (2020). FDA approves Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma.
- IQVIA. (2022). The Global Oncology Market Report.
- Incyte Corporation. (2022). Monjuvi (Tafasitamab) product monograph.
- PhRMA. (2021). The Development and Price of Monoclonal Antibodies.
- FDA. (2023). Biosimilar Development and Regulation.
